L Giovanelli1,2, C Aresta1,2, V Favero1,2, M Bonomi1,2, B Cangiano1,2, C Eller-Vainicher3, G Grassi3, V Morelli3, F Pugliese4, A Falchetti1, L Gennari5, A Scillitani4, L Persani1,2, I Chiodini6,7. 1. Unit for Bone Metabolism Diseases and Diabetes and Lab of Endocrine and Metabolic Research, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Via Magnasco 2, 20149, Milan, Italy. 2. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 3. Unit of Endocrinology, Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico, Milan, Italy. 4. Unit of Endocrinology and Diabetology "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, FG, Italy. 5. Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. 6. Unit for Bone Metabolism Diseases and Diabetes and Lab of Endocrine and Metabolic Research, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Via Magnasco 2, 20149, Milan, Italy. iacopo.chiodini@unimi.it. 7. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. iacopo.chiodini@unimi.it.
Abstract
PURPOSE: Classic Cushing's syndrome (CS) is a severe disease characterized by central obesity, hypertension, easy bruising, striae rubrae, buffalo hump, proximal myopathy and hypertricosis. However, several CS cases have also been reported with unusual or camouflaged manifestations. In recent years, several authors investigated the prevalence of "hidden hypercortisolism" (HidHyCo) among subjects affected with bone fragility, hypertension and type 2 diabetes mellitus (DM2). The prevalence of the HidHyCo is estimated to be much higher than that of classic CS. However, similarly to classic CS, HidHyCo is known to increase the risk of fractures, cardiovascular disease and mortality. METHODS: We reviewed all published cases of unusual presentations of hypercortisolism and studies specifically assessing the HidHyCo prevalence in diabetic, osteoporotic and hypertensive patients. RESULTS: We found 49 HidHyCo cases, in whom bone fragility, hypertension and diabetes were the presenting manifestations of an otherwise silent hypercortisolism. Amongst these cases, 34.7%, 32.7%, 6.1% and 19.0%, respectively, had bone fragility, hypertension, DM2 or hypertension plus DM2 as the sole clinical manifestations of HidHyCo. Overall, 25% of HidHyCo cases were of pituitary origin, and bone fragility was the very prevalent first manifestation among them. In population studies, it is possible to estimate that 1-4% of patients with apparent primary osteoporosis has a HidHyCo and the prevalence of this condition among diabetics ranges between 3.4 and 10%. CONCLUSION: These data indicate that patients with resistant or suddenly worsening hypertension or DM2 or unexplainable bone fragility should be screened for HidHyCo using the most recently approved sensitive cut-offs.
PURPOSE: Classic Cushing's syndrome (CS) is a severe disease characterized by central obesity, hypertension, easy bruising, striae rubrae, buffalo hump, proximal myopathy and hypertricosis. However, several CS cases have also been reported with unusual or camouflaged manifestations. In recent years, several authors investigated the prevalence of "hidden hypercortisolism" (HidHyCo) among subjects affected with bone fragility, hypertension and type 2 diabetes mellitus (DM2). The prevalence of the HidHyCo is estimated to be much higher than that of classic CS. However, similarly to classic CS, HidHyCo is known to increase the risk of fractures, cardiovascular disease and mortality. METHODS: We reviewed all published cases of unusual presentations of hypercortisolism and studies specifically assessing the HidHyCo prevalence in diabetic, osteoporotic and hypertensive patients. RESULTS: We found 49 HidHyCo cases, in whom bone fragility, hypertension and diabetes were the presenting manifestations of an otherwise silent hypercortisolism. Amongst these cases, 34.7%, 32.7%, 6.1% and 19.0%, respectively, had bone fragility, hypertension, DM2 or hypertension plus DM2 as the sole clinical manifestations of HidHyCo. Overall, 25% of HidHyCo cases were of pituitary origin, and bone fragility was the very prevalent first manifestation among them. In population studies, it is possible to estimate that 1-4% of patients with apparent primary osteoporosis has a HidHyCo and the prevalence of this condition among diabetics ranges between 3.4 and 10%. CONCLUSION: These data indicate that patients with resistant or suddenly worsening hypertension or DM2 or unexplainable bone fragility should be screened for HidHyCo using the most recently approved sensitive cut-offs.
Authors: Charlotte Steffensen; Alberto M Pereira; Olaf M Dekkers; Jens Otto L Jørgensen Journal: Eur J Endocrinol Date: 2016-06-27 Impact factor: 6.664
Authors: Andrea Osswald; Timo Deutschbein; Christina M Berr; Eva Plomer; Anne Mickisch; Katrin Ritzel; Jochen Schopohl; Felix Beuschlein; Martin Fassnacht; Stefanie Hahner; Martin Reincke Journal: Eur J Endocrinol Date: 2018-06-06 Impact factor: 6.664
Authors: Elena Valassi; Brooke Swearingen; Hang Lee; Lisa B Nachtigall; Daniel A Donoho; Anne Klibanski; Beverly M K Biller Journal: J Clin Endocrinol Metab Date: 2009-10-22 Impact factor: 5.958
Authors: A Toini; A Dolci; E Ferrante; E Verrua; E Malchiodi; E Sala; A G Lania; I Chiodini; P Beck-Peccoz; M Arosio; A Spada; G Mantovani Journal: Eur J Endocrinol Date: 2015-04 Impact factor: 6.664
Authors: Elena Valassi; Iacopo Chiodini; Richard A Feelders; Cornelie D Andela; Margueritta Abou-Hanna; Sarah Idres; Antoine Tabarin Journal: Endocr Connect Date: 2022-06-24 Impact factor: 3.221